Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

07.03.2022 | main topic

Experimental laboratory biomarkers in multiple sclerosis

verfasst von: Borros Arneth, Jörg Kraus

Erschienen in: Wiener Medizinische Wochenschrift

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Background

Multiple sclerosis (MS) is a chronic autoimmune disorder of the central nervous system; the cause of this condition remains unknown. Researchers have analyzed different biomarkers related to MS. Here, experimental laboratory biomarkers for MS are identified and analyzed.

Methods

The current study examined articles investigating biomarkers for MS. Records were obtained from the PubMed, LILACS, and EBSCO databases using an identical search strategy and terms that included “multiple sclerosis,” “MS,” and “biomarkers.” In the current review, we also focus on lesser known biomarkers that have not yet been established for use in clinical practice.

Results

Previous studies have explored molecular substances that may help diagnose MS and manage its adverse effects. Commonly studied factors include neurofilaments, sCD163, CXCL13, NEO, NF‑L, OPN, B cells, T cells, and integrin-binding proteins.

Conclusions

Interactions between environmental and genetic factors have been implicated in the development of MS. Previous investigations have identified a wide range of biomarkers that can be used for diagnosis and disease management. These molecules and their associated studies provide vital insight and data to help primary physicians improve clinical and health outcomes for MS patients.

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Literatur
1.
Zurück zum Zitat von Büdingen HC, Gulati M, Kuenzle S, Fischer K, Rupprecht TA, Goebels N. Clonally expanded plasma cells in the cerebrospinal fluid of patients with central nervous system autoimmune demyelination produce “oligoclonal bands. J Neuroimmunol. 2010;218(1–2):134–9. von Büdingen HC, Gulati M, Kuenzle S, Fischer K, Rupprecht TA, Goebels N. Clonally expanded plasma cells in the cerebrospinal fluid of patients with central nervous system autoimmune demyelination produce “oligoclonal bands. J Neuroimmunol. 2010;218(1–2):134–9.
2.
Zurück zum Zitat Thompson S, Jones J, Cox A, Compston D, Coles A. B‑cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J Clin Immunol. 2010;30(1):99–105. PubMed Thompson S, Jones J, Cox A, Compston D, Coles A. B‑cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J Clin Immunol. 2010;30(1):99–105. PubMed
6.
Zurück zum Zitat Wang H, Naghavi M, Allen C, Barber R, Bhutta Z, Carter A, et al. GBD 2015 mortality and causes of death collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388(10053):1459–544. Wang H, Naghavi M, Allen C, Barber R, Bhutta Z, Carter A, et al. GBD 2015 mortality and causes of death collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388(10053):1459–544.
7.
Zurück zum Zitat Sormani MP, Signori A, Siri P, De Stefano N. Time to first relapse as an endpoint in multiple sclerosis clinical trials. Mult Scler. 2013;19:466–74. PubMed Sormani MP, Signori A, Siri P, De Stefano N. Time to first relapse as an endpoint in multiple sclerosis clinical trials. Mult Scler. 2013;19:466–74. PubMed
19.
Zurück zum Zitat Sormani MP, Tintorè M, Rovaris M, Rovira A, Vidal X, Bruzzi P, et al. Will Rogers phenomenon in multiple sclerosis. Ann Neurol. 2008;64:428–33. PubMed Sormani MP, Tintorè M, Rovaris M, Rovira A, Vidal X, Bruzzi P, et al. Will Rogers phenomenon in multiple sclerosis. Ann Neurol. 2008;64:428–33. PubMed
20.
Zurück zum Zitat Runia TF, Hop WC, de Rijke YB, Buljevac D, Hintzen RQ. Lower serum vitamin D levels are associated with higher relapse risk in multiple sclerosis. Neurology. 2012;79:261–6. PubMed Runia TF, Hop WC, de Rijke YB, Buljevac D, Hintzen RQ. Lower serum vitamin D levels are associated with higher relapse risk in multiple sclerosis. Neurology. 2012;79:261–6. PubMed
22.
Zurück zum Zitat Teunissen CE, Iacobaeus E, Khademi M. Combination of CSF N‑acetylaspartate and neurofilaments in multiple sclerosis. Neurology. 2009;72(15):1322–9. PubMed Teunissen CE, Iacobaeus E, Khademi M. Combination of CSF N‑acetylaspartate and neurofilaments in multiple sclerosis. Neurology. 2009;72(15):1322–9. PubMed
24.
Zurück zum Zitat Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B‑cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358:676–88. PubMed Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B‑cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358:676–88. PubMed
26.
Zurück zum Zitat Barkhof F, Rocca M, Francis G, et al. Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta-1a. Ann Neurol. 2003;53:718–24. PubMed Barkhof F, Rocca M, Francis G, et al. Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta-1a. Ann Neurol. 2003;53:718–24. PubMed
27.
Zurück zum Zitat Filippi M, Rocca MA, Ciccarelli O, et al. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol. 2016;15:292–303. PubMedPubMedCentral Filippi M, Rocca MA, Ciccarelli O, et al. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol. 2016;15:292–303. PubMedPubMedCentral
30.
Zurück zum Zitat Kuhle J, Leppert D, Petzold A, et al. Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Neurology. 2011;76(14):1206–13. PubMed Kuhle J, Leppert D, Petzold A, et al. Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Neurology. 2011;76(14):1206–13. PubMed
31.
Zurück zum Zitat Comabella M, Montalbana X. Body fluid biomarkers in multiple sclerosis. Lancet Neurol. 2014;13:113–26. PubMed Comabella M, Montalbana X. Body fluid biomarkers in multiple sclerosis. Lancet Neurol. 2014;13:113–26. PubMed
32.
Zurück zum Zitat Teunissen CE, Khalil M. Neurofilaments as biomarkers in multiple sclerosis. Mult Scler. 2012;18(5):552–6. PubMed Teunissen CE, Khalil M. Neurofilaments as biomarkers in multiple sclerosis. Mult Scler. 2012;18(5):552–6. PubMed
33.
Zurück zum Zitat Salzer J, Svenningsson A, Sundstrom P. Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler. 2010;16(3):287–92. PubMed Salzer J, Svenningsson A, Sundstrom P. Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler. 2010;16(3):287–92. PubMed
34.
Zurück zum Zitat Martinez MA, Olsson B, Bau L. Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis. Mult Scler. 2015;21(5):550–61. PubMedPubMedCentral Martinez MA, Olsson B, Bau L. Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis. Mult Scler. 2015;21(5):550–61. PubMedPubMedCentral
37.
Zurück zum Zitat Modvig S, Degn M, Sander B. Cerebrospinal fluid neurofilament light chain levels predict visual outcome after optic neuritis. Mult Scler. 2016;22(5):590–8. PubMed Modvig S, Degn M, Sander B. Cerebrospinal fluid neurofilament light chain levels predict visual outcome after optic neuritis. Mult Scler. 2016;22(5):590–8. PubMed
38.
Zurück zum Zitat Novakova L, Zetterberg H, Sundström P, Axelsson M, Khademi M, Gunnarsson M, et al. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology. 2017;89(22):2230–7. PubMedPubMedCentral Novakova L, Zetterberg H, Sundström P, Axelsson M, Khademi M, Gunnarsson M, et al. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology. 2017;89(22):2230–7. PubMedPubMedCentral
39.
Zurück zum Zitat Gama PD, Machado LD, Livramento JA, Gomes HR, Adoni T, Lino AM, et al. Study of oligoclonal bands restricted to the cerebrospinal fluid in multiple sclerosis patients in the city of São Paulo. Arq Neuropsiquiatr. 2009;67:1017–22. PubMed Gama PD, Machado LD, Livramento JA, Gomes HR, Adoni T, Lino AM, et al. Study of oligoclonal bands restricted to the cerebrospinal fluid in multiple sclerosis patients in the city of São Paulo. Arq Neuropsiquiatr. 2009;67:1017–22. PubMed
40.
Zurück zum Zitat Srivastava R, Aslam M, Kalluri SR, Schirmer L, Buck D, Tackenberg B, et al. Potassium channel KIR4. 1 as an immune target in multiple sclerosis. N Engl J Med. 2012;367(2):115–23. PubMedPubMedCentral Srivastava R, Aslam M, Kalluri SR, Schirmer L, Buck D, Tackenberg B, et al. Potassium channel KIR4. 1 as an immune target in multiple sclerosis. N Engl J Med. 2012;367(2):115–23. PubMedPubMedCentral
41.
Zurück zum Zitat Deisenhammer F, Zetterberg H, Fitzner B, Zettl UK. The cerebrospinal fluid in multiple sclerosis. Front Immunol. 2019;10:726. PubMedPubMedCentral Deisenhammer F, Zetterberg H, Fitzner B, Zettl UK. The cerebrospinal fluid in multiple sclerosis. Front Immunol. 2019;10:726. PubMedPubMedCentral
42.
Zurück zum Zitat Toscano S, Patti F. CSF biomarkers in multiple sclerosis: beyond neuroinflammation. Neurol Neuroimmunol Neuroinflamm. 2021;8(1):14–41. Toscano S, Patti F. CSF biomarkers in multiple sclerosis: beyond neuroinflammation. Neurol Neuroimmunol Neuroinflamm. 2021;8(1):14–41.
43.
Zurück zum Zitat Senel M, Tumani H, Lauda F, Presslauer S, Mojib-Yezdani R, Otto M, et al. Cerebrospinal fluid immunoglobulin kappa light chain in clinically isolated syndrome and multiple sclerosis. PLoS One. 2014;9(4):e88680. PubMedPubMedCentral Senel M, Tumani H, Lauda F, Presslauer S, Mojib-Yezdani R, Otto M, et al. Cerebrospinal fluid immunoglobulin kappa light chain in clinically isolated syndrome and multiple sclerosis. PLoS One. 2014;9(4):e88680. PubMedPubMedCentral
44.
Zurück zum Zitat Senel M, Mojib-Yezdani F, Braisch U, Bachhuber F, Lewerenz J, Ludolph AC, et al. CSF free light chains as a marker of intrathecal immunoglobulin synthesis in multiple sclerosis: a blood-CSF barrier related evaluation in a large cohort. Front Immunol. 2019;10:641. PubMedPubMedCentral Senel M, Mojib-Yezdani F, Braisch U, Bachhuber F, Lewerenz J, Ludolph AC, et al. CSF free light chains as a marker of intrathecal immunoglobulin synthesis in multiple sclerosis: a blood-CSF barrier related evaluation in a large cohort. Front Immunol. 2019;10:641. PubMedPubMedCentral
45.
Zurück zum Zitat Schwenkenbecher P, Konen FF, Wurster U, Jendretzky KF, Gingele S, Sühs KW, et al. The persisting significance of oligoclonal bands in the dawning era of kappa free light chains for the diagnosis of multiple sclerosis. Int J Mol Sci. 2018;19(12):3796. PubMedCentral Schwenkenbecher P, Konen FF, Wurster U, Jendretzky KF, Gingele S, Sühs KW, et al. The persisting significance of oligoclonal bands in the dawning era of kappa free light chains for the diagnosis of multiple sclerosis. Int J Mol Sci. 2018;19(12):3796. PubMedCentral
48.
Zurück zum Zitat Comabella M, Craig DW, Morcillo-Suárez C. Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. Arch Neurol. 2009;66:972–8. PubMed Comabella M, Craig DW, Morcillo-Suárez C. Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. Arch Neurol. 2009;66:972–8. PubMed
49.
Zurück zum Zitat Thebault S, Abdoli M, Fereshtehnejad SM, Tessier D, Tabard-Cossa V, Freedman MS. Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis. Sci Rep. 2020;10(1):1–1. Thebault S, Abdoli M, Fereshtehnejad SM, Tessier D, Tabard-Cossa V, Freedman MS. Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis. Sci Rep. 2020;10(1):1–1.
50.
Zurück zum Zitat Bushnell SE, Zhao Z, Stebbins CC. Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS. Neurology. 2012;79:531–7. PubMedPubMedCentral Bushnell SE, Zhao Z, Stebbins CC. Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS. Neurology. 2012;79:531–7. PubMedPubMedCentral
51.
Zurück zum Zitat Sanz Diaz CT, de las Heras Flórez S, Carretero Perez M, Hernández Pérez MÁ, Martín García V. Evaluation of kappa index as a tool in the diagnosis of multiple sclerosis: implementation in routine screening procedure. Front Neurol. 2012;12:1259. Sanz Diaz CT, de las Heras Flórez S, Carretero Perez M, Hernández Pérez MÁ, Martín García V. Evaluation of kappa index as a tool in the diagnosis of multiple sclerosis: implementation in routine screening procedure. Front Neurol. 2012;12:1259.
54.
Zurück zum Zitat Stilund M, Gjelstrup MC, Petersen T, Møller HJ, Rasmussen PV, Christensen T. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel. PLoS One. 2015;10(4):e119681. PubMedPubMedCentral Stilund M, Gjelstrup MC, Petersen T, Møller HJ, Rasmussen PV, Christensen T. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel. PLoS One. 2015;10(4):e119681. PubMedPubMedCentral
55.
Zurück zum Zitat Kaplan B, Aizenbud BM, Golderman S, Yaskariev R, Sela BA. Free light chain monomers in the diagnosis of multiple sclerosis. J Neuroimmunol. 2010;229:263–71. PubMed Kaplan B, Aizenbud BM, Golderman S, Yaskariev R, Sela BA. Free light chain monomers in the diagnosis of multiple sclerosis. J Neuroimmunol. 2010;229:263–71. PubMed
56.
Zurück zum Zitat Durante L, Zaaraoui W, Rico A. Intrathecal synthesis of IgM measured after a first demyelinating event suggestive of multiple sclerosis is associated with subsequent MRI brain lesion accrual. Mult Scler. 2012;18:587–91. PubMed Durante L, Zaaraoui W, Rico A. Intrathecal synthesis of IgM measured after a first demyelinating event suggestive of multiple sclerosis is associated with subsequent MRI brain lesion accrual. Mult Scler. 2012;18:587–91. PubMed
57.
Zurück zum Zitat Ferraro D, Simone AM, Bedin R. Cerebrospinal fluid oligoclonal IgM bands predict early conversion to clinically definite multiple sclerosis in patients with the clinically isolated syndrome. J Neuroimmunol. 2013;257:76–81. PubMed Ferraro D, Simone AM, Bedin R. Cerebrospinal fluid oligoclonal IgM bands predict early conversion to clinically definite multiple sclerosis in patients with the clinically isolated syndrome. J Neuroimmunol. 2013;257:76–81. PubMed
59.
Zurück zum Zitat Khademi M, Kockum I, Andersson ML. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult Scler. 2012;17:335–43. Khademi M, Kockum I, Andersson ML. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult Scler. 2012;17:335–43.
60.
Zurück zum Zitat Zhong X, Wang H, Dai Y. Cerebrospinal fluid levels of CXCL13 are elevated in neuromyelitis optica. J Neuroimmunol. 2012;240–241:104–8. Zhong X, Wang H, Dai Y. Cerebrospinal fluid levels of CXCL13 are elevated in neuromyelitis optica. J Neuroimmunol. 2012;240–241:104–8.
61.
Zurück zum Zitat Schmidt C, Plate A, Angele B. A prospective study on the role of CXCL13 in Lyme neuroborreliosis. Neurology. 2013;76:1051–8. Schmidt C, Plate A, Angele B. A prospective study on the role of CXCL13 in Lyme neuroborreliosis. Neurology. 2013;76:1051–8.
62.
Zurück zum Zitat Takano R, Misu T, Takahashi T, Sato S, Fujihara K, Itoyama Y. Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology. 2012;75:208–16. Takano R, Misu T, Takahashi T, Sato S, Fujihara K, Itoyama Y. Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology. 2012;75:208–16.
63.
Zurück zum Zitat Hauser SL, Waubant E, Arnold DL. B‑cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2013;358:676–88. Hauser SL, Waubant E, Arnold DL. B‑cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2013;358:676–88.
64.
Zurück zum Zitat Naismith RT, Piccio L, Lyons JA. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology. 2012;74:1860–7. Naismith RT, Piccio L, Lyons JA. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology. 2012;74:1860–7.
65.
Zurück zum Zitat Gnanapavan S, Grant D, Illes-Toth E, Lakdawala N, Keir G, Giovannoni G. Neural cell adhesion molecule—description of a CSF ELISA method and evidence of reduced levels in selected neurological disorders. J Neuroimmunol. 2010;225:118–22. PubMed Gnanapavan S, Grant D, Illes-Toth E, Lakdawala N, Keir G, Giovannoni G. Neural cell adhesion molecule—description of a CSF ELISA method and evidence of reduced levels in selected neurological disorders. J Neuroimmunol. 2010;225:118–22. PubMed
67.
Zurück zum Zitat Khademi M, Kockum I, Andersson ML, Iacobaeus E, Brundin L, Sellebjerg F. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult Scler. 2011;17(3):335–43. PubMed Khademi M, Kockum I, Andersson ML, Iacobaeus E, Brundin L, Sellebjerg F. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult Scler. 2011;17(3):335–43. PubMed
68.
Zurück zum Zitat Dobson R, Topping J, Davis A, Thompson E, Giovannoni G. Cerebrospinal fluid and urinary biomarkers in multiple sclerosis. Acta Neurol Scand. 2013;128(5):321–7. PubMed Dobson R, Topping J, Davis A, Thompson E, Giovannoni G. Cerebrospinal fluid and urinary biomarkers in multiple sclerosis. Acta Neurol Scand. 2013;128(5):321–7. PubMed
69.
Zurück zum Zitat Cenit MD, Blanco-Kelly F, de las Heras V. Glypican 5 is an interferon-beta response gene: a replication study. Mult Scler. 2009;15:913–7. PubMed Cenit MD, Blanco-Kelly F, de las Heras V. Glypican 5 is an interferon-beta response gene: a replication study. Mult Scler. 2009;15:913–7. PubMed
71.
Zurück zum Zitat Carlsen HS, Baekkevold ES, Morton HC, Haraldsen G, Brandtzaeg P. Monocyte-like and mature macrophages produce CXCL13 (B cell-attracting chemokine 1) in inflammatory lesions with lymphoid neogenesis. Blood. 2004;104(10):3021–7. PubMed Carlsen HS, Baekkevold ES, Morton HC, Haraldsen G, Brandtzaeg P. Monocyte-like and mature macrophages produce CXCL13 (B cell-attracting chemokine 1) in inflammatory lesions with lymphoid neogenesis. Blood. 2004;104(10):3021–7. PubMed
72.
Zurück zum Zitat Romme Christensen J, Bornsen L, Khademi M, Olsson T, Jensen PE, Sorensen PS. CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis. Mult Scler. 2013;19(7):877–84. PubMed Romme Christensen J, Bornsen L, Khademi M, Olsson T, Jensen PE, Sorensen PS. CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis. Mult Scler. 2013;19(7):877–84. PubMed
73.
Zurück zum Zitat Bahlo M, Booth DR, Broadley S, Brown MA, Foote SJ, Griffiths LR, et al. Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat Genet. 2009;41(7):824–8. Bahlo M, Booth DR, Broadley S, Brown MA, Foote SJ, Griffiths LR, et al. Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat Genet. 2009;41(7):824–8.
74.
Zurück zum Zitat Schwartz ES, Chapman BP, Duberstein PR, Weinstock-Guttman B, Benedict RH. The NEO-FFI in multiple sclerosis: internal consistency, factorial validity, and correspondence between self and informant reports. Assessment. 2011;18(1):39–49. PubMed Schwartz ES, Chapman BP, Duberstein PR, Weinstock-Guttman B, Benedict RH. The NEO-FFI in multiple sclerosis: internal consistency, factorial validity, and correspondence between self and informant reports. Assessment. 2011;18(1):39–49. PubMed
75.
Zurück zum Zitat The ANZgene Consortium. Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat Genet. 2009;41:824–8. The ANZgene Consortium. Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat Genet. 2009;41:824–8.
76.
Zurück zum Zitat Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B‑cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):66–8. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B‑cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):66–8.
77.
Zurück zum Zitat Kamm CP, Uitdehaag BM, Polman CH. Multiple sclerosis: current knowledge and future outlook. Eur Neurol. 2014;72(3–4):32–41. Kamm CP, Uitdehaag BM, Polman CH. Multiple sclerosis: current knowledge and future outlook. Eur Neurol. 2014;72(3–4):32–41.
79.
Zurück zum Zitat Canwell B, Bar-Or A, Arnold DL. Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. Lancet Neurol. 2011;10:436–45. Canwell B, Bar-Or A, Arnold DL. Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. Lancet Neurol. 2011;10:436–45.
80.
Zurück zum Zitat Lovato L, Willis SN, Rodig SJ, Caron T, Almendinger SE, Howell OW, et al. Related B cell clones populate the meninges and parenchyma of patients with multiple sclerosis. Brain. 2011;134(2):34–41. Lovato L, Willis SN, Rodig SJ, Caron T, Almendinger SE, Howell OW, et al. Related B cell clones populate the meninges and parenchyma of patients with multiple sclerosis. Brain. 2011;134(2):34–41.
82.
Zurück zum Zitat Hemmer B, Kerschensteiner M, Korn T. Role of the innate and adaptive immune responses in the course of multiple sclerosis. Lancet Neurol. 2015;14(4):406–19. PubMed Hemmer B, Kerschensteiner M, Korn T. Role of the innate and adaptive immune responses in the course of multiple sclerosis. Lancet Neurol. 2015;14(4):406–19. PubMed
83.
Zurück zum Zitat Mowry EM, Waubant E, McCulloch CE. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol. 2012;72:234–40. PubMedPubMedCentral Mowry EM, Waubant E, McCulloch CE. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol. 2012;72:234–40. PubMedPubMedCentral
84.
Zurück zum Zitat Harris S, Comi G, Cree BAC, Arnold DL, Steinman L, Sheffield JK, et al. Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: post hoc analysis of phase 3 ozanimod trials. Eur J Neurol. 2021;28(11):3722–30. https://​doi.​org/​10.​1111/​ene.​15009. CrossRefPubMed Harris S, Comi G, Cree BAC, Arnold DL, Steinman L, Sheffield JK, et al. Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: post hoc analysis of phase 3 ozanimod trials. Eur J Neurol. 2021;28(11):3722–30. https://​doi.​org/​10.​1111/​ene.​15009. CrossRefPubMed
85.
Zurück zum Zitat Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278–86. PubMedPubMedCentral Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278–86. PubMedPubMedCentral
86.
Zurück zum Zitat Ingram G, Hakobyan S, Hirst CL, Harris CL, Pickersgill TP, Cossburn MD, et al. Complement regulator factor H as a serum biomarker of multiple sclerosis disease state. Brain. 2010;133(6):1602–11. PubMed Ingram G, Hakobyan S, Hirst CL, Harris CL, Pickersgill TP, Cossburn MD, et al. Complement regulator factor H as a serum biomarker of multiple sclerosis disease state. Brain. 2010;133(6):1602–11. PubMed
Metadaten
Titel
Experimental laboratory biomarkers in multiple sclerosis
verfasst von
Borros Arneth
Jörg Kraus
Publikationsdatum
07.03.2022
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-022-00920-7